Lazard Asset Management’s iShares Biotechnology ETF IBB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $192K | Buy |
1,138
+249
| +28% | +$42.6K | ﹤0.01% | 1636 |
|
|
2025
Q4 | $150K | Buy |
889
+664
| +295% | +$108K | ﹤0.01% | 1690 |
|
|
2025
Q3 | $32.5K | Hold |
225
| – | – | ﹤0.01% | 1756 |
|
|
2025
Q2 | $28K | Sell |
225
-150
| -40% | -$18.4K | ﹤0.01% | 2090 |
|
|
2025
Q1 | $47K | Buy |
+375
| New | +$50.8K | ﹤0.01% | 2006 |
|
|
2024
Q3 | – | Sell |
-315
| Closed | -$43K | – | 2348 |
|
|
2024
Q2 | $43K | Hold |
315
| – | – | ﹤0.01% | 1952 |
|
|
2024
Q1 | $43K | Hold |
315
| – | – | ﹤0.01% | 1745 |
|
|
2023
Q4 | $42K | Hold |
315
| – | – | ﹤0.01% | 1927 |
|
|
2023
Q3 | $38K | Hold |
315
| – | – | ﹤0.01% | 1924 |
|
|
2023
Q2 | $39K | Hold |
315
| – | – | ﹤0.01% | 1907 |
|
|
2023
Q1 | $40K | Hold |
315
| – | – | ﹤0.01% | 1862 |
|
|
2022
Q4 | $41K | Hold |
315
| – | – | ﹤0.01% | 1902 |
|
|
2022
Q3 | $36K | Hold |
315
| – | – | ﹤0.01% | 1922 |
|
|
2022
Q2 | $37K | Hold |
315
| – | – | ﹤0.01% | 1937 |
|
|
2022
Q1 | $41K | Hold |
315
| – | – | ﹤0.01% | 1833 |
|
|
2021
Q4 | $48K | Hold |
315
| – | – | ﹤0.01% | 1759 |
|
|
2021
Q3 | $50K | Hold |
315
| – | – | ﹤0.01% | 1687 |
|
|
2021
Q2 | $51K | Hold |
315
| – | – | ﹤0.01% | 1594 |
|
|
2021
Q1 | $47K | Hold |
315
| – | – | ﹤0.01% | 1456 |
|
|
2020
Q4 | $47K | Hold |
315
| – | – | ﹤0.01% | 1409 |
|
|
2020
Q3 | $42K | Hold |
315
| – | – | ﹤0.01% | 1234 |
|
|
2020
Q2 | $43K | Hold |
315
| – | – | ﹤0.01% | 1265 |
|
|
2020
Q1 | $33K | Hold |
315
| – | – | ﹤0.01% | 1327 |
|
|
2019
Q4 | $37K | Hold |
315
| – | – | ﹤0.01% | 1116 |
|
|
2019
Q3 | $31K | Hold |
315
| – | – | ﹤0.01% | 1023 |
|
|
2019
Q2 | $34K | Buy |
+315
| New | +$33.5K | ﹤0.01% | 1134 |
|
|
2018
Q1 | – | Sell |
-31,775
| Closed | -$3.39M | – | 1083 |
|
|
2017
Q4 | $3.39M | Sell |
31,775
-34,120
| -52% | -$3.65M | 0.01% | 593 |
|
|
2017
Q3 | $7.33M | Hold |
65,895
| – | – | 0.01% | 499 |
|
|
2017
Q2 | $6.81M | Buy |
65,895
+19,188
| +41% | +$1.89M | 0.01% | 500 |
|
|
2017
Q1 | $4.57M | Sell |
46,707
-1,449
| -3% | -$139K | 0.01% | 568 |
|
|
2016
Q4 | $4.26M | Buy |
48,156
+17,106
| +55% | +$1.56M | 0.01% | 545 |
|
|
2016
Q3 | $3M | Buy |
+31,050
| New | +$2.95M | 0.01% | 588 |
|
|
2014
Q3 | – | Sell |
-30
| Closed | -$2K | – | 1068 |
|
|
2014
Q2 | $2K | Buy |
+30
| New | +$2.36K | ﹤0.01% | 984 |
|
Other funds holding IBB
CB
Lazard Asset Management's IBB Position: Q1 2026 in Review
Lazard Asset Management increased its iShares Biotechnology ETF (IBB) stake by 28% in Q1 2026, buying an estimated $42.6K and bringing the position to 1,138 shares worth $192K. The position accounts for ﹤0.01% of the portfolio, ranked #1636.
Lazard Asset Management first reported a position in IBB in Q2 2014 and has held it in 33 quarters since. The position peaked at $7.33M in Q3 2017. 917 funds tracked by Wall St. Rank hold IBB as of Q1 2026.
- Lazard Asset Management held 1,138 shares of iShares Biotechnology ETF worth $192K as of Q1 2026.
- Lazard Asset Management bought 249 iShares Biotechnology ETF shares in Q1 2026, an estimated $42.6K.
- iShares Biotechnology ETF made up ﹤0.01% of Lazard Asset Management's portfolio in Q1 2026, its #1636 holding.
- Lazard Asset Management first reported a position in iShares Biotechnology ETF in Q2 2014 and has held it in 33 quarters since.
- Lazard Asset Management's iShares Biotechnology ETF position peaked at $7.33M in Q3 2017.
- 917 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.
Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.